Company intelligence / Profile preview

Rampart Equipment

La Jolla, California, United Statesrampartequipment.com ↗

Ownership: Private
Development stage: Other

Overview

Rampart Bioscience has developed a proprietary non-viral DNA delivery platform called HALO, designed to enable potent, durable, and redosable gene therapies. Their lead program targets hypophosphatasia (HPP), a rare genetic bone disorder. Early preclinical work demonstrates promise in overcoming durability and safety limitations seen with earlier viral and nonviral gene therapies. No clinical results have been published yet.

Therapeutic areas: Rare Diseases
Modalities: DNA therapyGene therapyNon-viral gene therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Rampart Equipment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rampart Equipment.

Explore the full profile